CellWise reads single-cell gene expression and turns it into a story a clinician can act on: what's driving the symptoms a standard panel can't see, which systems are involved, and the exact next step.
One PBMC sample resolves 400+ biomarker genes across immune cell populations, scored into the risk-rated health domains that shape how a patient feels and functions, the signal a standard panel averages away.
CellWise organizes single-cell analysis around the health categories that shape how a patient actually feels and functions, and resolves the drivers a standard panel can't see.
Not just that a marker is high, but which cell populations are driving it, so the source is visible and addressable.
Glycolytic versus oxidative efficiency across immune cell types, the axis that anticipates how a patient responds to therapy.
Early cardiometabolic risk read from immune and metabolic signals, before it surfaces on a standard workup.
Th1 skew, NK cytotoxicity, and IFNG context that meaningfully informs a reproductive-immunology conversation.
Three examples of the reasoning CellWise surfaces, and the decision each one sharpens.
CellWise converges TLR9, IRF7, and TLR7 in plasmacytoid dendritic cells with IFNG in NK cells into a single coherent interferonopathy signature.
The platform flags Sermorelin and Tesamorelin as use-with-caution in that immune context, and rates GLP-1 agonists optimal with an explicit monocyte-targeting rationale.
A Th1 skew, elevated NK cytotoxicity, and IFNG elevation give the immune context behind the presentation.
◆ Illustrative reads from simulated beta review, shown to demonstrate the platform's reasoning. Not from a specific patient.
The clinical home base. Use-case assessments, immuno-metabolic phenotyping, the therapeutic target map, stress profiling, and more, all in one report.
The quantitative, visual view of the patient's raw biomarker data, shown as a population-vs-patient overview.
A filterable, gene-level interface over the patient's complete dataset, exposing the top cell populations carrying each signal.
Test a clinical hypothesis against the patient's own molecular data and re-run it in seconds.
Assay-independent surveillance across dosing phases, peptide-specific labs, and wearable trends, with no repeat sequence required.
Immune age, senescence, and the 12 hallmarks from one PBMC sample, for cell-resolved biological aging.
Re-assay a patient and see the gene-expression deltas across key biomarkers, so you see what has shifted since the last screen.
Pick the workspace tuned to how your practice actually prescribes, tracks, and bills.
Match compounds to phenotype, with an explicit AVOID list and a live Clinical Surveillance Feed.
Cell-resolved biological age and white-labeled reports, without the hours of prep.
See what a 'normal' panel misses, across 400+ genes and immune cell populations.
Benchmark recovery at the transcript level, screen over screen.
License, co-brand, or white-label the platform into your own menu of services.
What the Bioscreen is, what it costs, and how to ask your own practitioner for it.
Three independent reviewers read the same donor in isolation, and converged on the same labs, the same contraindication, and the same candidacy call.
It reads like a narrative, not a spreadsheet. The mechanism, the systems involved, and the next step arrive in one card, instead of an afternoon spent interpreting gene lists myself.
What sets it apart is that every finding comes with a decision attached: the specific lab to order or the compound to reconsider, not just another number to sit with.
A conventional panel reads normal while the patient is still symptomatic. CellWise resolves which cells are dysregulated and why, which is a different level of resolution than anything I can order today.
Join the founding pilot: up to five of your own patients at $1,485 each, 29% below the standard rate, invoiced only for the ones you send. Founding rates lock for twelve months if you go forward, and every pilot practice is a design partner with a say on what gets built. Open to the first fifty founding practices.